Myxovirus Resistance Protein A as a Marker of Viral Cause of Illness in Children Hospitalized with an Acute Infection.
Adolescent
Anti-Bacterial Agents
/ therapeutic use
Antiviral Agents
/ therapeutic use
Bacterial Infections
/ diagnosis
Biomarkers
/ blood
Child
Child, Preschool
Diagnosis, Differential
Female
Fever
/ diagnosis
Humans
Infant
Male
Myxovirus Resistance Proteins
/ blood
Orthomyxoviridae
/ genetics
Orthomyxoviridae Infections
/ diagnosis
Staphylococcal Protein A
Virus Diseases
/ drug therapy
bacterial infection
interferon inducible protein
myxovirus resistance protein A
viral infection
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
23 02 2022
23 02 2022
Historique:
pubmed:
27
1
2022
medline:
15
3
2022
entrez:
26
1
2022
Statut:
ppublish
Résumé
A biomarker for viral infection could improve the differentiation between viral and bacterial infections and reduce antibiotic overuse. We examined blood myxovirus resistance protein A (MxA) as a biomarker for viral infections in children with an acute infection. We recruited 251 children presenting with a clinical suspicion of serious bacterial infection, determined by need for a blood bacterial culture collection, and 14 children with suspected viral infection at two pediatric emergency departments. All children were aged between 4 weeks and 16 years. We classified cases according to the viral, bacterial, or other etiology of the final diagnosis. The ability of MxA to differentiate between viral and bacterial infections was assessed. The median blood MxA levels were 467 (interquartile range, 235 to 812) μg/L in 39 children with a viral infection, 469 (178 to 827) μg/L in 103 children with viral-bacterial coinfection, 119 (68 to 227) μg/L in 75 children with bacterial infection, and 150 (101 to 212) μg/L in 26 children with bacterial infection and coincidental virus finding (
Identifiants
pubmed: 35080443
doi: 10.1128/spectrum.02031-21
pmc: PMC8791186
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antiviral Agents
0
Biomarkers
0
Myxovirus Resistance Proteins
0
Staphylococcal Protein A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0203121Références
Am J Respir Crit Care Med. 2016 Apr 1;193(7):772-82
pubmed: 26571305
Emerg Med J. 2012 May;29(5):379-82
pubmed: 21609944
Nat Med. 2004 Aug;10(8):811-3
pubmed: 15247911
Pediatrics. 2006 May;117(5):1695-701
pubmed: 16651326
Acta Paediatr. 2004 Feb;93(2):169-73
pubmed: 15046268
J Virol. 2007 Jul;81(14):7776-85
pubmed: 17494065
Pediatr Infect Dis J. 2010 Jun;29(6):519-23
pubmed: 20051928
J Clin Microbiol. 2011 Jul;49(7):2631-6
pubmed: 21543571
Pediatr Infect Dis J. 2014 Nov;33(11):e273-9
pubmed: 25093971
Pediatr Int. 2007 Feb;49(1):31-5
pubmed: 17250502
Pediatr Infect Dis J. 2008 Dec;27(12):1103-7
pubmed: 18978518
Pediatrics. 2015 Apr;135(4):e985-93
pubmed: 25802344
BMJ. 2010 Apr 20;340:c1594
pubmed: 20406860
J Clin Med. 2017 Oct 07;6(10):
pubmed: 28991170
Thorax. 2002 May;57(5):438-41
pubmed: 11978922
J Immunol. 1993 Mar 1;150(5):1715-26
pubmed: 7679692
J Infect Dis. 2018 Jun 20;218(2):179-188
pubmed: 29228381
Pediatrics. 2014 Mar;133(3):e538-45
pubmed: 24567027
Pediatr Res. 2006 Dec;60(6):770-4
pubmed: 17065575
Ann Emerg Med. 2012 Nov;60(5):591-600
pubmed: 22921165
Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S87-97
pubmed: 14730275
Ann Med. 2018 Aug;50(5):420-429
pubmed: 29775092
J Clin Virol. 2015 Jan;62:8-13
pubmed: 25542463
Eur Clin Respir J. 2015 Dec 10;2:28245
pubmed: 26672961
BMJ. 2011 Jun 08;342:d3082
pubmed: 21653621
PLoS One. 2016 Nov 15;11(11):e0163262
pubmed: 27846213
J Infect. 2017 Apr;74(4):385-392
pubmed: 28077283
J Infect Dis. 2017 Nov 27;216(9):1099-1103
pubmed: 28968760
Pediatr Emerg Care. 2006 Oct;22(10):689-99
pubmed: 17047467
J Interferon Cytokine Res. 2011 Jan;31(1):79-87
pubmed: 21166595